Aug 2026· Life· Vol 16, pp. 1290· 0 citations· 31 references
Medicine
TL;DR
The emerging findings highlight the importance of jointly considering biological sex and APOE ε4 status to improve the characterization of Alzheimer’s disease heterogeneity and support precision medicine approaches.
Abstract
Background: The interaction between sex, APOE ε4 status, and clinical progression in Alzheimer’s Disease (AD) remains a subject of debate. While females are often considered at higher risk for AD, the underlying structural neuroanatomical trajectories and how they are modulated by genotype are not fully elucidated. This study aims to evaluate how sex and the APOE ε4 genotype interact to influence longitudinal brain atrophy across three clinical groups. Methods: We analyzed longitudinal data from 2400 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), stratified by clinical group (i.e., cognitively normal, mild cognitive impairment, and AD), sex, and APOE ε4 carrier status. Using Type III Sum of Squares ANCOVA, we modeled the longitudinal variation in brain volume, controlling for baseline brain volume, and baseline severity of neurocognitive impairment and age at entry. Results: While main effects of sex and APOE genotype were not significant, the triple interaction (APOE * Sex * Clinical Group) was marginally significant (p = 0.051). Post hoc analysis revealed a distinct pattern of structural dimorphism within the AD cohort among APOE ε4-negative individuals with females exhibiting significantly greater structural preservation compared to males (Mean difference = 11.32, p = 0.051). Among APOE ε4 carriers, atrophy trajectories for males and females were statistically indistinguishable (p = 0.922), potentially suggesting that the ε4 allele exerts a dominant neurodegenerative influence that overrides sex-specific physiological differences. Conclusions: These emerging findings highlight the importance of jointly considering biological sex and APOE ε4 status to improve the characterization of Alzheimer’s disease heterogeneity and support precision medicine approaches.
Aβ pathology modifies the longitudinal cognitive trajectory associated with APOE ε4 in pre-dementia adults over a 2-year period, consistent with the antagonistic pleiotropy framework.
Hongchun Wei, Tianhao Zhang, Zhigang Liang et al.· Frontiers in Aging Neuroscie...· 0 citations
In this Indian cohort, APOE ε4 homozygosity reflects increased susceptibility and familial aggregation of AD but does not confer a more severe or distinct phenotype, suggesting ancestry- specific expression of APOE ε4 gene-dose effects.
Pratibha Vinod, C. Arampady, Somdatta Sen et al.· Neurodegenerative Disease Ma...· 0 citations
BAG is a reliable non-invasive marker of structural brain health sensitive to AD pathology and to modifiable AD risk and supports its relevance for early risk stratification and prevention-oriented research.
E. Kuhn, G. Antopoulos, L. Kleineidam et al.· medRxiv· 0 citations
The left hippocampus is a critical mediator linking specific plasma lipids to AD progression, with an additional vascular pathway via white matter hyperintensities emerging after comorbidity adjustment, supporting a dual neurodegenerative–vascular pathway.
Among CU individuals, plasma p-tau217 was associated with subsequent MCI/dementia due to AD and showed the most extensive associations with longitudinal AD-related brain atrophy, compared with SPARE-BA or R-indices capturing subcortical, diffuse cortical, or perisylvian atrophy.
Murat Bilgel, Ishaan Shah, Jasmine M. Cooper et al.· medRxiv· 0 citations
BACKGROUND
Demonstrating the specificity of plasma biomarkers to AD-related neurodegeneration would add support to their prognostic and diagnostic clinical use.
METHOD
Participants from the Baltimore Longitudinal Study of Aging were cognitively unimpaired at the time of their plasma Aβ42/Aβ40, GFAP, NfL (Quanterix Ne...
Murat Bilgel, Ishaan Shah, Jasmine M. Cooper et al.· Alzheimer's & Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.